Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
UCB Pharma
ClinicalTrials.gov Identifier:
NCT01495793
First received: December 16, 2011
Last updated: May 5, 2014
Last verified: May 2014

December 16, 2011
May 5, 2014
December 2011
April 2014   (final data collection date for primary outcome measure)
  • Apparent Total Body Clearance (Cl/f) of Unconjugated Rotigotine 0.5 mg/24 h (2.5 cm^2) [ Time Frame: 0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on last day per dose step ] [ Designated as safety issue: No ]
    Apparent total body clearance (Cl/f) of unconjugated Rotigotine 0.5 mg/24 h (2.5 cm^2).
  • Apparent Total Body Clearance (Cl/f) of Unconjugated Rotigotine 1 mg/24 h (5 cm^2) [ Time Frame: 0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on last day per dose step ] [ Designated as safety issue: No ]
    Apparent total body clearance (Cl/f) of unconjugated Rotigotine 1 mg/24 h (5 cm^2).
  • Apparent Total Body Clearance (Cl/f) of Unconjugated Rotigotine 2 mg/24 h (10 cm^2) [ Time Frame: 0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on last day per dose step ] [ Designated as safety issue: No ]
    Apparent total body clearance (Cl/f) of unconjugated Rotigotine 2 mg/24 h (10 cm^2).
  • Apparent Total Body Clearance (Cl/f) of Unconjugated Rotigotine 3 mg/24 h (15 cm^2) [ Time Frame: 0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on last day per dose step ] [ Designated as safety issue: No ]
    Apparent total body clearance (Cl/f) of unconjugated Rotigotine 3 mg/24 h (15 cm^2).
  • Volume of Distribution (Vd) of Unconjugated Rotigotine 0.5 mg/24 h (2.5 cm^2) [ Time Frame: 0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on last day per dose step ] [ Designated as safety issue: No ]
    Volume of distribution (Vd) of unconjugated Rotigotine 0.5 mg/24 h (2.5 cm^2).
  • Volume of Distribution (Vd) of Unconjugated Rotigotine 1 mg/24 h (5 cm^2) [ Time Frame: 0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on last day per dose step ] [ Designated as safety issue: No ]
    Volume of distribution (Vd) of unconjugated Rotigotine 1 mg/24 h (5 cm^2).
  • Volume of Distribution (Vd) of Unconjugated Rotigotine 2 mg/24 h (10 cm^2) [ Time Frame: 0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on last day per dose step ] [ Designated as safety issue: No ]
    Volume of distribution (Vd) of unconjugated Rotigotine 2 mg/24 h (10 cm^2).
  • Volume of Distribution (Vd) of Unconjugated Rotigotine 3 mg/24 h (15 cm^2) [ Time Frame: 0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on last day per dose step ] [ Designated as safety issue: No ]
    Volume of distribution (Vd) of unconjugated Rotigotine 3 mg/24 h (15 cm^2).
  • Area Under the Curve (AUCss) of unconjugated rotigotine 0.2 mg /24 h (1 cm^2). [ Time Frame: 0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on last day per dose step ] [ Designated as safety issue: No ]
    AUCss at steady state for rotigotine patch 0.2 mg/24 h (1 cm^2).
  • Area Under the Curve (AUCss) of unconjugated rotigotine 0.5 mg/24 h (2.5 cm^2). [ Time Frame: 0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on last day per dose step ] [ Designated as safety issue: No ]
    AUCss at steady state for rotigotine patch 0.5 mg/24 h (2.5 cm^2).
  • Area Under the Curve (AUCss) of unconjugated rotigotine 1 mg/24 h (5 cm^2). [ Time Frame: 0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on last day per dose step ] [ Designated as safety issue: No ]
    AUCss at steady state for rotigotine patch 1 mg/24 h (5 cm^2).
  • Area Under the Curve (AUCss) of unconjugated rotigotine 2 mg/24 h (10 cm^2). [ Time Frame: 0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on last day per dose step ] [ Designated as safety issue: No ]
    AUCss at steady state for rotigotine patch 2 mg/24 h (10 cm^2).
  • Area Under the Curve (AUCss) of unconjugated rotigotine 3 mg/24 h (15 cm^2). [ Time Frame: 0 h (predose), 1 h, 2 h, 7-12 h and 22-24 h on last day per dose step ] [ Designated as safety issue: No ]
    AUCss at steady state for rotigotine patch 3 mg/24 h (15 cm^2).
Complete list of historical versions of study NCT01495793 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome
A Multicenter, Open-Label, 2-Group, Dose Escalation Study of Monotherapy Administration of Rotigotine in Pediatric Subjects With Idiopathic Restless Legs Syndrome

This will be a multicenter, open-label, dose-escalation, Phase 2A study with multiple monotherapy administration of the Rotigotine transdermal system. The study will be conducted in adolescent subjects (13 to <18 years of age) with idiopathic Restless Legs Syndrome (RLS).

Study design was changed and an amendment was prepared accordingly.

Interventional
Phase 2
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Restless Legs Syndrome
Drug: Rotigotine
Titration of Rotigotine transdermal patch one week per dose 0.5 mg/24 h (2.5 cm^2)- 1 mg/24 h (5 cm^2)- 2 mg/24 h (10 cm^2)- 3 mg/24 h (15 cm^2)
Experimental: All Subjects

Titration of Rotigotine transdermal patch one week per dose

0.5 mg/24 h (2.5 cm^2)- 1 mg/24 h (5 cm^2)- 2 mg/24 h (10 cm^2)-3 mg/24 h (15 cm^2)

Intervention: Drug: Rotigotine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
April 2014
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject or parent/legal representative is considered reliable and capable of adhering to the protocol
  • Subject is male or female, and is ≥13 and <18 years of age at Visit 2/Baseline
  • Subject weighs ≥40 kg at Visit 2/Baseline
  • Subject's Body Mass Index (BMI) is less than the 95th percentile for his or her age at Visit 2/Baseline
  • Subject meets the diagnosis of RLS based on the proposed 2011 Revised International Restless Legs Syndrome Study Group Diagnostic Criteria
  • Subject's RLS symptoms cause significant distress or impairment
  • At Visit 2/Baseline, subject has a Periodic Limb Movement Index (PLMI) ≥5 during at least 1 of the 5 nights prior to Baseline as measured by the activity monitors
  • At Visit 2/Baseline, subject has a score of ≥15 on the IRLS Rating Scale
  • At Visit 2/Baseline, subject scores ≥4 points on the Clinical Global Impression (CGI) Item 1 assessment
  • Subject receiving supplemental iron has been on a stable dose for at least 3 months prior to Visit 1/Screening Period

Exclusion Criteria:

  • Previously participated in this study or received previous treatment with rotigotine
  • Participated in another study of an investigational medicinal product (IMP) or a medical device within the last 3 months prior to Visit 1/Screening Period or is currently participating in another study of an IMP or a medical device
  • Subject's RLS symptoms are restricted only to the ankles or knees
  • RLS symptoms are due to renal insufficiency (uremia) or iron deficiency anemia
  • Previous treatment with dopamine agonists within a period of 14 days prior to Visit 2/Baseline or L-dopa within 7 days prior to Visit 2/Baseline
  • Failed to respond to previous dopaminergic therapy
  • Any medical or psychiatric condition, which in the opinion of the investigator, would jeopardize or compromise the subject's well being or ability to participate
  • Subject has a lifetime history of suicide attempt or has suicidal ideation in the past 6 months
  • Evidence of an impulse control disorder (ICD)
  • History or current symptoms of sleep apnea, narcolepsy, sleep attacks/sudden onset of sleep, or myoclonus epilepsy
  • Concomitant diseases such as peripheral neuropathy, muscle fasciculation, painful legs and moving toes, fibromyalgia, rheumatoid arthritis, or sickle cell disease
  • Serum ferritin level <15 ng/mL
  • Subject has not attempted at least 1 non-pharmacological intervention for the management of RLS (eg, sleep hygiene, exercise)
  • Prior history of psychotic episodes
  • History of chronic alcohol or drug abuse within 12 months prior Screening Period
  • Clinically relevant cardiac dysfunction and/or arrhythmias
  • Hemoglobin level below the lower limit of normal
  • Clinically relevant renal dysfunction (serum creatinine >1.5 mg/dL)
  • Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin level greater than or equal to 2 times the upper limit of normal
  • History or presence of clinical signs of any malignant neoplasm including suspicious undiagnosed skin lesion (which may be melanoma), melanoma, or a history of melanoma
  • Currently receiving or has received treatment with any of the following within 28 days prior to Visit 2/Baseline: neuroleptics, antidepressants, anxiolytic drugs, opioids, monoamine oxidase (MAO) inhibitors, or sedative antihistamines
  • Currently receiving treatment with any of the following: benzodiazepines, hypnotics, anticonvulsants, central alpha-adrenergic agonists, or melatonin; unless treatment is for RLS only, in which case a Wash-Out Period of at least 14 days prior to Visit 2/Baseline is required
  • Currently receiving stimulant therapy for attention deficit hyperactivity disorder (ADHD); a Wash-Out Period of at least 7 days prior to Visit 2/Baseline is required
  • Pregnant, nursing, or is a woman of childbearing potential who is not surgically sterile, or does not consistently use 2 combined medically acceptable methods of contraception (including at least 1 barrier method), unless not sexually active
  • Unwilling to abstain from caffeine after 4pm each evening within 7 days prior to Visit 2/Baseline and for the duration of the study
  • Pursues shift work or performs other continuous non-disease-related life conditions, which do not allow regular sleep at night
  • Subject has a QT correction (QTc) interval of ≥500 ms at Visit 1/Screening Period or Visit 2/Baseline. Bazett's correction method must be used for the correction of the QT interval
  • Symptomatic orthostatic hypotension with a decrease of blood pressure (BP) from supine to standing position of ≥20 mmHg in systolic blood pressure (SBP) or of ≥10 mmHg in diastolic blood pressure (DBP) taken from the 5 minute supine and 1 and/or 3 minute standing measurements
  • A known hypersensitivity to any of the components of the study medication, such as a history of significant skin hypersensitivity to adhesives, known hypersensitivity to other transdermal medications or has unresolved contact dermatitis or eczema
Both
13 Years to 17 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01495793
SP1004
No
UCB Pharma
UCB Pharma
Not Provided
Study Director: UCB Clinical Trial Call Center 1-877-822-9493 (UCB)
UCB Pharma
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP